Table 4.

Characteristics of subjects with inconsistent IGRA results over the 4-week study period

Subject no.Age (yr)SexcTB riskIGRAResult from visit (study day)d:Overall trenda
1 (0)2 (+7)3 (+14)4 (+21)5 (+28)
741MMediumQFTPositive (0.45)Positive (1.05)Negative (0.00)Negative (0.00)Inconsistent
T-SPOTNegative (1/0)Negative (0/0)Negative (0/0)Negative (4/1)Negative
842FLowQFTPositive (0.49)bNegative (0.00)Negative (0.00)Negative (0.00)Negative (0.00)Inconsistent
T-SPOTNegative (0/0)Negative (1/0)Negative (0/0)Negative (0/0)Negative (0/0)Negative
1234FLowQFTNegative (0.00)Positive (2.58)Negative (0.00)Negative (0.01)Negative (0.00)Inconsistent
T-SPOTNegative (0/0)Negative (0/0)Negative (1/1)Negative (0/0)Negative (0/0)Negative
1348FLowQFTNegative (0.00)Positive (1.09)Negative (0.00)Negative (0.00)Inconsistent
T-SPOTNegative (1/1)Negative (1/0)Negative (1/0)Negative (0/2)Negative
1439FLowQFTNegative (0.00)Positive (0.82)Negative (0.02)Negative (0.00)Inconsistent
T-SPOTNegative (0/3)Negative (1/1)Negative (2/2)Negative (2/2)Negative
1748FLowQFTPositive (0.59)bNegative (0.20)Negative (0.11)Negative (0.19)Negative (0.31)Inconsistent
T-SPOTNegative (0/3)Negative (1/1)Negative (0/3)Negative (0/5)Negative (0/3)Negative
1920MLowQFTPositive (0.77)Negative (0.08)Negative (0.00)Negative (0.00)Negative (0.00)Inconsistent
T-SPOTNegative (0/0)Negative (0/0)Negative (0/0)Negative (0/0)Negative (0/0)Negative
2247FMediumQFTNegative (0.28)Negative (0.00)Negative (0.10)Negative (0.09)Negative
T-SPOTPositive (1/10)Positive (0/8)Negative (0/5)Negative (0/2)Inconsistent
2449FMediumQFTPositive (0.37)bNegative(0.20)Negative (0.21)Negative (0.26)Inconsistent
T-SPOTNegative (0/2)Negative (0/3)Negative (5/0)Negative (0/3)Negative
2541MMediumQFTPositive (0.60)Positive (0.49)Positive (1.63)Positive (0.62)Positive (0.64)Positive
T-SPOTPositive (100/30)Positive (100/100)Negative (0/1)Negative (3/0)Negative (3/0)Inconsistent
2648FLowQFTNegative (0.26)Positive (0.52)bNegative (0.33)Negative (0.14)Inconsistent
T-SPOTPositive (0/8)Positive (2/24)Positive (0/6)Positive (3/14)Positive
2744FMediumQFTPositive (1.04)Positive (0.61)Positive (1.66)Positive (0.96)Negative (0.24)bInconsistent
T-SPOTPositive (5/10)Positive (12/15)Positive (4/10)Positive (14/17)Positive (13/10)Positive
3255FMediumQFTNegative (0.19)Negative (0.03)Negative (0.12)Negative (0.26)Negative
T-SPOTPositive (8/4)bPositive (6/0)Negative (2/0)Negative (3/1)Inconsistent
  • a Conversions were defined as a baseline IFN-γ concentration of <0.35 IU/ml, followed by an increase across the threshold of ≥0.35 IU/ml. Reversions were defined as the opposite progression.

  • b IFN-γ responses within proposed borderline zones from 0.2 to 0.7 IU/ml and 4 to 8 SFCs which showed changes in results from negative to positive or vice versa according to the manufacturers' thresholds.

  • c M, male; F, female.

  • d Values in parentheses represent IFN-γ responses in IU/ml and SFCs (ESAT-6 panel/CFP-10 panel) for the QFT and the T-SPOT assay, respectively.